Generation Bio (NASDAQ: GBIO) furnishes Q3 2025 financial results release

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Generation Bio Co. filed a current report to let investors know it has released its latest quarterly financial results. The company issued a press release covering its results for the quarter ended September 30, 2025, and attached that release as an exhibit to this report.

The press release is furnished, not filed, which means it is provided for information but is not automatically subject to certain legal liabilities or incorporated into other regulatory documents unless specifically referenced. The report is signed by Yalonda Howze, the company’s Interim Chief Executive Officer and President.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

11/05/2025 - 04:12 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 5, 2025

Generation Bio Co.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-39319

81-4301284

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

301 Binney Street

Cambridge, MA

02142

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 655-7500

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	GBIO	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2025, Generation Bio Co. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description
99.1		Press Release Issued by Generation Bio Co. on November 5, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GENERATION BIO CO.

Date: November 5, 2025	By:	/s/ Yalonda Howze
		Name: Yalonda Howze
		Title: Interim Chief Executive Officer and President

Source: View Original Filing on SEC EDGAR

FAQ

What did Generation Bio Co. (GBIO) report in this Form 8-K?

Generation Bio Co. reported that it issued a press release announcing its financial results for the quarter ended September 30, 2025, and furnished that release as Exhibit 99.1.

Which period do the reported Generation Bio Co. (GBIO) financial results cover?

The financial results discussed in the press release furnished with this report cover the quarter ended September 30, 2025.

Where can investors find the detailed quarterly results for Generation Bio Co. (GBIO)?

The detailed quarterly results are contained in the press release identified as Exhibit 99.1, which is furnished with this report and incorporated by reference.

Are Generation Bio Co. (GBIO) quarterly results considered filed with the SEC in this 8-K?

No. The company states that the information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act.

Who signed this Generation Bio Co. (GBIO) Form 8-K?

The report was signed on behalf of Generation Bio Co. by Yalonda Howze, who is identified as Interim Chief Executive Officer and President.

What exhibits are included with this Generation Bio Co. (GBIO) Form 8-K?

The report includes Exhibit 99.1, which is the press release issued on November 5, 2025, and Exhibit 104, which is the cover page interactive data file embedded within the Inline XBRL document.